NCT05026567View on ClinicalTrials.gov

Bioavailability Study of Midazolam Administered as a Solution by Conventional Syringe or ZENEO®

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 9, 2022

Primary Completion Date

July 14, 2022

Study Completion Date

July 15, 2022

Conditions
Healthy
Interventions
DRUG

2 ml of DORMICUM® Midazolam Hydrochloride (15 mg/3 mL)

Intramuscular injection

COMBINATION_PRODUCT

ZENEO® Midazolam (10 mg/0.625 mL) on bare skin in thigh

Intramuscular injection

COMBINATION_PRODUCT

ZENEO® Midazolam (10 mg / 0.625 mL) on bare skin in ventrogluteal area

Intramuscular injection

COMBINATION_PRODUCT

ZENEO® Midazolam (10 mg / 0.625 mL) through clothing in thigh

Intramuscular injection

Trial Locations (1)

9301

FARMOVS Pty Ltd, Bloemfontein

Sponsors

Lead Sponsor

Crossject
All Listed Sponsors
lead

Crossject

INDUSTRY

NCT05026567 - Bioavailability Study of Midazolam Administered as a Solution by Conventional Syringe or ZENEO® | Biotech Hunter | Biotech Hunter